Janumet, Lantus — Competitive Intelligence Brief

Janumet, Lantus (Janumet, Lantus) competitive landscape: 0 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: DPP-4 inhibitor + biguanide (Janumet); long-acting basal insulin (Lantus). Area: Diabetes.

marketed DPP-4 inhibitor + biguanide (Janumet); long-acting basal insulin (Lantus) DPP-4 enzyme, metformin (AMPK pathway), insulin receptor (Lantus) Diabetes Small molecule

Target snapshot

Janumet, Lantus (Janumet, Lantus) — Chinese University of Hong Kong. Janumet combines sitagliptin (a DPP-4 inhibitor) with metformin to lower blood glucose by increasing incretin levels and reducing hepatic glucose production, while Lantus is a long-acting basal insulin that provides steady glucose control.

Comparator set

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
Janumet, Lantus TARGET	Janumet, Lantus	Chinese University of Hong Kong	marketed	DPP-4 inhibitor + biguanide (Janumet); long-acting basal insulin (Lantus)	DPP-4 enzyme, metformin (AMPK pathway), insulin receptor (Lantus)

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (DPP-4 inhibitor + biguanide (Janumet); long-acting basal insulin (Lantus) class)

1. Chinese University of Hong Kong · 1 drug in this class